Not applicableUnknownNCT01329068What this trial is testingPatient Empowerment by Group Medical ConsultationsWho this might be right forBreast CancerBRCA Mutation Radboud University Medical Center 320
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07743268What this trial is testingPersonalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALSWho this might be right forAmyotrophic Lateral Sclerosis (ALS) n-Lorem Foundation 6
Testing effectiveness (Phase 2)UnknownNCT00299897What this trial is testingSP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV PatientsWho this might be right forHIV InfectionsHuman Immunodeficiency Virus Samaritan Pharmaceuticals, Inc 60
Testing effectiveness (Phase 2)UnknownNCT03647956What this trial is testingAtezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsWho this might be right forNSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation The University of Hong Kong 40
Testing effectiveness (Phase 2)Study completedNCT00586651What this trial is testingOpen-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisWho this might be right forPolycythemia VeraEssential Thrombocytosis Cephalon 39
Large-scale testing (Phase 3)Study completedNCT04185363What this trial is testingAn Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)Who this might be right forProgressive Familial Intrahepatic Cholestasis (PFIC) Mirum Pharmaceuticals, Inc. 84
Testing effectiveness (Phase 2)Ended earlyNCT04933695What this trial is testingSotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentWho this might be right forNon-small Cell Lung Cancer Amgen 42
Early research (Phase 1)UnknownNCT03645200What this trial is testingTreatment of Carrying TP53 Harmful MutationsWho this might be right forAdvanced Cancer Tianjin Medical University Second Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187What this trial is testingPembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsWho this might be right forNon-squamous NSCLC Shanghai Chest Hospital 54
Testing effectiveness (Phase 2)UnknownNCT05102292What this trial is testingThe Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationWho this might be right forAnaplastic Thyroid CancerATC Shanghai Henlius Biotech 25
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607What this trial is testingASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCWho this might be right forLocally Advanced or Metastatic NSCLC Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)UnknownNCT05016544What this trial is testingInetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT05983237What this trial is testingFluzoparib in Combination With Camrelizumab and Temozolomide in Advanced MelanomaWho this might be right forMelanoma Jun Guo 50
Early research (Phase 1)Study completedNCT01225536What this trial is testingDose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS MutationsWho this might be right forSolid Tumor ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 24
Large-scale testing (Phase 3)Study completedNCT02756611What this trial is testingEvaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)Who this might be right forChronic Lymphocytic Leukemia AbbVie 258
Testing effectiveness (Phase 2)Looking for participantsNCT06128551What this trial is testingStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Study completedNCT00588445What this trial is testingPhase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor GeneWho this might be right forLung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer Memorial Sloan Kettering Cancer Center 65
Testing effectiveness (Phase 2)Study completedNCT02927301What this trial is testingAtezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)Who this might be right forNon-Small Cell Lung Cancer Genentech, Inc. 181
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175What this trial is testingTesting GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 70
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930What this trial is testingPhase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationWho this might be right forResidual or Recurrent Grade 2 IDH Mutant Glioma Servier 57